204 related articles for article (PubMed ID: 3690030)
1. Almitrine effect on nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease (COPD).
Daskalopoulou E; Patakas D; Tsara V; Kazis A; Maniki E; Zoglopitis F
Bull Eur Physiopathol Respir; 1987 Aug; 23 Suppl 11():185s-190s. PubMed ID: 3690030
[TBL] [Abstract][Full Text] [Related]
2. Almitrine improves oxygenation when both awake and asleep in patients with hypoxia and carbon dioxide retention caused by chronic bronchitis and emphysema.
Connaughton JJ; Douglas NJ; Morgan AD; Shapiro CM; Critchley JA; Pauly N; Flenley DC
Am Rev Respir Dis; 1985 Aug; 132(2):206-10. PubMed ID: 4026044
[TBL] [Abstract][Full Text] [Related]
3. The effect of long-term almitrine therapy on sleep hypoxaemia in patients with chronic airways obstruction.
Racineux JL; Meslier N; Hubert P
Bull Eur Physiopathol Respir; 1987 Aug; 23 Suppl 11():183s-184s. PubMed ID: 3690029
[TBL] [Abstract][Full Text] [Related]
4. [Sleep and nocturnal desaturation of patients with chronic obstructive bronchopneumopathies. Effects of almitrine bismesylate administered orally].
Kurtz D; Weitzenblum E; Krieger J; Reitzer B; Roujansky P
Rev Mal Respir; 1985; 2 Suppl 1():S45-52. PubMed ID: 2870547
[TBL] [Abstract][Full Text] [Related]
5. One year treatment with almitrine improves hypoxaemia but does not increase pulmonary artery pressure in COPD patients.
Weitzenblum E; Schrijen F; Apprill M; Prefaut C; Yernault JC
Eur Respir J; 1991 Nov; 4(10):1215-22. PubMed ID: 1804669
[TBL] [Abstract][Full Text] [Related]
6. Almitrine bismesylate: a long-term placebo-controlled double-blind study in COAD--Vectarion International Multicentre Study Group.
Voisin C; Howard P; Ansquer JC
Bull Eur Physiopathol Respir; 1987 Aug; 23 Suppl 11():169s-182s. PubMed ID: 3318971
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of almitrine bismesylate on oxygenation during wakefulness and sleep in chronic obstructive pulmonary disease.
Gothe B; Cherniack NS; Bachand RT; Szalkowski MB; Bianco KA
Am J Med; 1988 Mar; 84(3 Pt 1):436-44. PubMed ID: 2894764
[TBL] [Abstract][Full Text] [Related]
8. [The first Italian clinical experience with almitrine bismesylate].
Grassi V; Bottino G; Blasi A; Grassi C
Rev Mal Respir; 1985; 2 Suppl 1():S53-60. PubMed ID: 2870548
[TBL] [Abstract][Full Text] [Related]
9. [Almitrine bismesylate in chronic obstructive lung disease and persistent hypoxemia. Controlled double-blind study with oral administration].
Wuttke R; von Wichert P
Respiration; 1985; 48(4):285-95. PubMed ID: 3936140
[TBL] [Abstract][Full Text] [Related]
10. Comparison of almitrine bismesylate and medroxyprogesterone acetate on oxygenation during wakefulness and sleep in patients with chronic obstructive lung disease.
Daskalopoulou E; Patakas D; Tsara V; Zoglopitis F; Maniki E
Thorax; 1990 Sep; 45(9):666-9. PubMed ID: 2145654
[TBL] [Abstract][Full Text] [Related]
11. Sequential treatment with low dose almitrine bismesylate in hypoxaemic chronic obstructive airways disease.
Bardsley PA; Howard P; Tang O; Empey D; Harrison B; Peake MD; O'Reilly J; Riordan JF; Wilkinson J; Arnaud F
Eur Respir J; 1992 Oct; 5(9):1054-61. PubMed ID: 1426214
[TBL] [Abstract][Full Text] [Related]
12. A review of clinical studies carried out in Italy with almitrine bismesylate.
Grassi V; Tantucci C; Sorbini CA; Grassi C; Cerveri I; Rampulla C; Bottino G; Giacometti A; Blasi A; Pezza A
Eur J Respir Dis Suppl; 1986; 146():671-6. PubMed ID: 3536560
[TBL] [Abstract][Full Text] [Related]
13. Long term studies on almitrine bismesylate in COPD patients.
Bourgouin-Karaouni D; Mercier J; Prefaut C
Eur J Respir Dis Suppl; 1986; 146():695-701. PubMed ID: 3096767
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of almitrine bismesylate in COPD patients with chronic hypoxaemia.
Sans-Torres J; Domingo C; Morón A; Rué M; Marín A
Respir Med; 2003 Jun; 97(6):599-605. PubMed ID: 12814142
[TBL] [Abstract][Full Text] [Related]
15. Drug therapy of sleep-related hypoxaemia.
Weitzenblum E; Apprill M; Oswald M; Kurtz D
Lung; 1990; 168 Suppl():948-54. PubMed ID: 2143553
[TBL] [Abstract][Full Text] [Related]
16. Effects of almitrine bismesylate on nocturnal hypoxemia in patients with chronic bronchitis and obesity.
Marrone O; Milone F; Coppola P; Oddo S; Giannone G; Macaluso C; Bonsignore G
Eur J Respir Dis Suppl; 1986; 146():641-8. PubMed ID: 3096764
[TBL] [Abstract][Full Text] [Related]
17. Effects of almitrine on the ventilatory control, breathing pattern and maximal exercise tolerance in hypoxemic patients with chronic obstructive pulmonary disease.
Ribeiro SA; Jardim JR; Romaldini H; Novo NF; Nery LE
Braz J Med Biol Res; 1995 Aug; 28(8):859-67. PubMed ID: 8555987
[TBL] [Abstract][Full Text] [Related]
18. Sleep quality, carbon dioxide responsiveness and hypoxaemic patterns in nocturnal hypoxaemia due to chronic obstructive pulmonary disease (COPD) without daytime hypoxaemia.
Sandek K; Andersson T; Bratel T; Hellström G; Lagerstrand L
Respir Med; 1999 Feb; 93(2):79-87. PubMed ID: 10464857
[TBL] [Abstract][Full Text] [Related]
19. Dose-response and pharmacokinetic study with almitrine bismesylate after single oral administrations in COPD patients.
Bury T; Jeannot JP; Ansquer JC; Radermecker M
Eur Respir J; 1989 Jan; 2(1):49-55. PubMed ID: 2495983
[TBL] [Abstract][Full Text] [Related]
20. The effect of intravenously administered almitrine, a peripheral chemoreceptor agonist, on patients with chronic air-flow obstruction.
Powles AC; Tuxen DV; Mahood CB; Pugsley SO; Campbell EJ
Am Rev Respir Dis; 1983 Mar; 127(3):284-9. PubMed ID: 6131635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
